A tripledemic refers to the simultaneous surge of three respiratory viruses: COVID-19, influenza, and respiratory syncytial virus (RSV). The term gained widespread use during the winter of 2022-2023, when all three viruses circulated at high levels at the same time and strained hospital systems across the United States. While each of these viruses has its own seasonal pattern, pandemic-era disruptions to normal circulation created conditions for them to peak together in a way that hadn’t happened before.
Why Three Viruses Hit at Once
Before the COVID-19 pandemic, influenza and RSV followed predictable seasonal curves each fall and winter. But the lockdowns, masking, and social distancing measures of 2020 and 2021 disrupted those patterns. Fewer people got sick with flu and RSV during those years, which meant less natural immunity built up in the population. When restrictions lifted and social mixing returned to normal, all three viruses found large numbers of susceptible people at the same time.
During November 2022 through March 2023, the co-circulation of SARS-CoV-2, influenza, and RSV created the tripledemic that strained U.S. healthcare systems. The CDC noted that while this surge was intense, it also bolstered population-wide immunity against all three viruses, which shaped projections for subsequent seasons.
How These Viruses Overlap in Symptoms
One reason the tripledemic created so much confusion is that all three infections look similar in their early stages. Cough, fever, fatigue, sore throat, and body aches can show up with any of them. A few distinguishing features exist, though they aren’t reliable enough to diagnose by symptoms alone.
COVID-19 is more likely to cause a new loss of taste or smell, particularly in earlier variants, and shortness of breath. Influenza tends to hit hard and fast, with sudden high fever and severe muscle aches. RSV typically starts with cold-like symptoms but can progress to wheezing and difficulty breathing, especially in infants and older adults. In practice, the overlap is significant enough that testing is the only reliable way to tell them apart.
Testing for All Three at Once
Hospitals and clinics can now test for multiple respiratory viruses from a single nasal swab using multiplex PCR panels. These tests can screen for 17 or more viral pathogens simultaneously, making it possible to identify not just flu, COVID, and RSV but also other viruses like parainfluenza and adenovirus. The specificity of these panels is excellent, ranging from 93% to 100%, meaning false positives are rare. Sensitivity varies more depending on the specific virus and the test kit used, so a negative result doesn’t always rule out infection. Rapid at-home tests for COVID and flu are also widely available, though they’re less sensitive than lab-based PCR testing.
Can You Catch More Than One at a Time?
Co-infection with two respiratory viruses is possible, though your body has a built-in defense that makes it less likely. When one virus infects your respiratory tract, your cells detect it and release signaling proteins called interferons. These interferons trigger a broad antiviral defense in both the infected cells and their neighbors, temporarily making it harder for a second virus to gain a foothold. This phenomenon, known as viral interference, essentially creates a short window of nonspecific immunity.
How well this works depends on several factors: how strongly the first virus triggers the interferon response, how susceptible the second virus is to that response, and how much each virus can suppress the immune reaction. The protective window likely lasts as long as the body is actively fighting the first infection.
A large meta-analysis of 43 studies in children found that being infected with two respiratory viruses at the same time did not significantly increase the severity of illness. Co-infected children had similar hospital stays, similar needs for oxygen support, and similar rates of ICU admission compared to children with a single virus. That said, the role of specific virus combinations (like flu plus COVID specifically) remains less clear.
The Strain on Hospitals
The tripledemic’s biggest impact wasn’t necessarily that individual patients were sicker. It was that so many people got sick at the same time. A study of 38 children’s hospitals during the 2022 surge found that nearly half experienced their highest-ever peak emergency department and inpatient volumes that year. Among hospitals that hit new records, ED volumes were 16% higher than any previous peak, and ICU volumes were 17% higher.
The downstream effects compounded quickly. When inpatient beds filled up, patients backed up in emergency departments, increasing wait times. Pediatric EDs and children’s hospitals operating at capacity began refusing transfers, forcing general hospitals to manage complex pediatric cases they normally wouldn’t handle. This cascading pressure on the system, not the severity of any single virus, is what made the tripledemic a public health crisis.
Who Is Most Vulnerable
Each of the three viruses poses the greatest risk to overlapping but slightly different groups. Infants and toddlers are especially vulnerable to RSV, which is the leading cause of hospitalization in children under one year old. Older adults, particularly those 75 and above, face elevated risk from all three viruses. People with chronic heart disease, lung conditions like COPD or asthma, diabetes with organ damage, severe obesity, or weakened immune systems are at increased risk of severe illness from any of the three.
Vaccines and Prevention
For the first time, vaccines or immunizations are available for all three tripledemic viruses. COVID-19 vaccines are updated regularly to match circulating variants. Flu vaccines are reformulated each year based on which strains are dominant. During the 2024-2025 season, influenza A viruses predominated, split roughly evenly between H1N1 and H3N2 subtypes, while influenza B activity remained low.
RSV protection has expanded significantly. The CDC recommends a single dose of RSV vaccine for all adults 75 and older, and for adults 50 to 74 who have conditions that raise their risk of severe RSV illness. Three RSV vaccines are currently licensed for adults 50 and older, and two are approved for high-risk adults as young as 18. The RSV vaccine is not an annual shot; one dose completes the series for now. For infants, a monoclonal antibody given shortly after birth provides passive protection through the first RSV season.
The best time to get vaccinated for all three viruses is late summer or early fall, before respiratory virus season typically begins. Combination vaccines targeting both COVID and flu in a single shot are in advanced clinical trials, though early results have been mixed on achieving full protection against all flu strains.
Beyond vaccination, basic prevention measures remain effective. Face masks reduce transmission of respiratory viruses, with studies showing protective effects against influenza, SARS, and COVID-19. Handwashing, staying home when symptomatic, and improving indoor ventilation all reduce the chance of spreading or catching these infections during peak season.